However, promising first results for famitinib (PDGFR/c-kit/VEGFR inhibitor) in the context of immunotherapy were very recently reported from an open-label, single-arm, phase II study including patients with untreated, advanced, immunomodulatory triple-negative breast cancer, who received a novel combination of famitinib, camrelizumab (monoclonal antibody against PD-1) and nab-paclitaxel [134]. This evidence concerns the gene PDGFRB and triple-negative breast carcinoma.